Clinical Trial Update: A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and pharmacokinetics of apixaban vs VKA/LMWH in pediatric patients with congenital or acquired heart disease requiring anticoagu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Heart Disease
• Congenital Heart Disease
• Thrombosis

Drugs mentioned

• Apixaban (apixaban)
• Low molecular weight heparin (low molecular weight heparin)
• Vitamin K antagonists

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Thrombosis | Phase 2 | Status: COMPLETED | Results posted: 2022-05-18